A detailed history of Virtus Fund Advisers, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Virtus Fund Advisers, LLC holds 768 shares of NBIX stock, worth $94,172. This represents 0.44% of its overall portfolio holdings.

Number of Shares
768
Previous 768 -0.0%
Holding current value
$94,172
Previous $105,000 16.19%
% of portfolio
0.44%
Previous 0.42%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $2,486 - $2,720
19 Added 2.54%
768 $105,000
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $8,084 - $8,911
62 Added 9.02%
749 $103,000
Q4 2023

Feb 15, 2024

BUY
$106.07 - $132.76 $30,229 - $37,836
285 Added 70.9%
687 $90,000
Q3 2023

Nov 08, 2023

BUY
$94.02 - $117.1 $37,796 - $47,074
402 New
402 $45,000
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $1.63 Million - $1.91 Million
-17,726 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$58.53 - $77.59 $1.04 Million - $1.38 Million
17,726
17,726 $1.38 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.7B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Virtus Fund Advisers, LLC Portfolio

Follow Virtus Fund Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Fund Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus Fund Advisers, LLC with notifications on news.